Cale A D, Gero T W, Walker K R, Lo Y S, Welstead W J, Jaques L W, Johnson A F, Leonard C A, Nolan J C, Johnson D N
Research Laboratory, A. H. Robins Company, Inc., Richmond, Virginia 23261-6609.
J Med Chem. 1989 Sep;32(9):2178-99. doi: 10.1021/jm00129a026.
A series of novel benzo- and pyrido-1,4-oxazepinones and -thiones which represents a new structural class of compounds possessing H1 antihistaminic activity was synthesized, and the SARs were evaluated. The antihistaminic activity was determined by blockade of histamine-induced lethality in guinea pigs. The sedative potential was determined by comparison of the EEG profiles of the compounds with those of known sedating and nonsedating antihistamines. Several of the compounds were shown to possess potent H1 antihistaminic activity and to be free of the cortical slowing with synchronized waves and spindling activity found in the EEG of sedative antihistamines. One compound, 2-[2-(dimethylamino)ethyl]-3,4-dihydro-4-methylpyrido[3,2-f]-1,4- oxazepine-5(2H)-thione (rocastine) is currently undergoing clinical evaluation as a nonsedating H1 antihistamine.
合成了一系列新型苯并-和吡啶并-1,4-恶唑烷酮及-硫酮,它们代表了一类具有H1抗组胺活性的新型结构化合物,并对其构效关系进行了评估。通过阻断组胺诱导的豚鼠致死作用来测定抗组胺活性。通过比较化合物与已知镇静和非镇静抗组胺药的脑电图图谱来确定其镇静潜力。结果表明,其中几种化合物具有强效的H1抗组胺活性,且没有镇静抗组胺药脑电图中出现的皮层慢波伴同步波和纺锤波活动。一种化合物,2-[2-(二甲基氨基)乙基]-3,4-二氢-4-甲基吡啶并[3,2-f]-1,4-恶唑烷-5(2H)-硫酮(罗卡斯汀)目前正在作为非镇静性H1抗组胺药进行临床评估。